Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation

Alvaro Alonso, Richard F. MacLehose, Lin Y. Chen, Lindsay G.S. Bengtson, Alanna Chamberlain, Faye L. Norby, Pamela L. Lutsey

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: To assess the risk of liver injury hospitalisation in patients with atrial fibrillation (AF) after initiation of direct oral anticoagulants (DOACs) or warfarin and to determine predictors of liver injury hospitalisation in this population. Methods: We studied 113 717 patients (mean age 70, 39% women) with AF included in the MarketScan Commercial and Medicare Supplemental databases with a first prescription for oral anticoagulation after 4 November 2011, followed through 31 December 2014. Of these, 56 879 initiated warfarin, 17 286 initiated dabigatran, 30 347 initiated rivaroxaban and 9205 initiated apixaban. Liver injury hospitalisation and comorbidities were identified from healthcare claims. Results: During a median follow-up of 12 months, 960 hospitalisations with liver injury were identified. Rates of liver injury hospitalisation ( per 1000 person-years) by oral anticoagulant were 9.0 (warfarin), 4.0 (dabigatran), 6.6 (rivaroxaban) and 5.6 (apixaban). After multivariable adjustment, liver injury hospitalisation rates were lower in initiators of DOACs compared with warfarin: HR (95% CI) of 0.57 (0.46 to 0.71), 0.88 (0.75 to 1.03) and 0.70 (0.50 to 0.97) for initiators of dabigatran, rivaroxaban, and apixaban, respectively (vs. warfarin). Compared with dabigatran initiators, rivaroxaban initiators had a 56% increased risk of liver injury hospitalisation (HR 1.56, 95% CI 1.22 to 1.99). In addition to type of anticoagulant, prior liver, gallbladder and kidney disease, cancer, anaemia, heart failure and alcoholism significantly predicted liver injury hospitalisation. A predictive model including these variables had adequate discriminative ability (C-statistic 0.67, 95% CI 0.64 to 0.70). Conclusions: Among patients with non-valvular AF, DOACs were associated with lower risk of liver injury hospitalisation compared with warfarin, with dabigatran showing the lowest risk.

Original languageEnglish (US)
Pages (from-to)834-839
Number of pages6
JournalHeart
Volume103
Issue number11
DOIs
StatePublished - Jun 1 2017

Fingerprint

Anticoagulants
Atrial Fibrillation
Hospitalization
Prospective Studies
Warfarin
Liver
Wounds and Injuries
Gallbladder Diseases
Social Adjustment
Aptitude
Kidney Neoplasms
Kidney Diseases
Medicare
Alcoholism
Prescriptions
Comorbidity
Liver Diseases
Anemia
Heart Failure
Dabigatran

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Alonso, A., MacLehose, R. F., Chen, L. Y., Bengtson, L. G. S., Chamberlain, A., Norby, F. L., & Lutsey, P. L. (2017). Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation. Heart, 103(11), 834-839. https://doi.org/10.1136/heartjnl-2016-310586

Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation. / Alonso, Alvaro; MacLehose, Richard F.; Chen, Lin Y.; Bengtson, Lindsay G.S.; Chamberlain, Alanna; Norby, Faye L.; Lutsey, Pamela L.

In: Heart, Vol. 103, No. 11, 01.06.2017, p. 834-839.

Research output: Contribution to journalArticle

Alonso, A, MacLehose, RF, Chen, LY, Bengtson, LGS, Chamberlain, A, Norby, FL & Lutsey, PL 2017, 'Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation', Heart, vol. 103, no. 11, pp. 834-839. https://doi.org/10.1136/heartjnl-2016-310586
Alonso, Alvaro ; MacLehose, Richard F. ; Chen, Lin Y. ; Bengtson, Lindsay G.S. ; Chamberlain, Alanna ; Norby, Faye L. ; Lutsey, Pamela L. / Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation. In: Heart. 2017 ; Vol. 103, No. 11. pp. 834-839.
@article{1819a257ace64db2a1b186e31198f6a6,
title = "Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation",
abstract = "Objective: To assess the risk of liver injury hospitalisation in patients with atrial fibrillation (AF) after initiation of direct oral anticoagulants (DOACs) or warfarin and to determine predictors of liver injury hospitalisation in this population. Methods: We studied 113 717 patients (mean age 70, 39{\%} women) with AF included in the MarketScan Commercial and Medicare Supplemental databases with a first prescription for oral anticoagulation after 4 November 2011, followed through 31 December 2014. Of these, 56 879 initiated warfarin, 17 286 initiated dabigatran, 30 347 initiated rivaroxaban and 9205 initiated apixaban. Liver injury hospitalisation and comorbidities were identified from healthcare claims. Results: During a median follow-up of 12 months, 960 hospitalisations with liver injury were identified. Rates of liver injury hospitalisation ( per 1000 person-years) by oral anticoagulant were 9.0 (warfarin), 4.0 (dabigatran), 6.6 (rivaroxaban) and 5.6 (apixaban). After multivariable adjustment, liver injury hospitalisation rates were lower in initiators of DOACs compared with warfarin: HR (95{\%} CI) of 0.57 (0.46 to 0.71), 0.88 (0.75 to 1.03) and 0.70 (0.50 to 0.97) for initiators of dabigatran, rivaroxaban, and apixaban, respectively (vs. warfarin). Compared with dabigatran initiators, rivaroxaban initiators had a 56{\%} increased risk of liver injury hospitalisation (HR 1.56, 95{\%} CI 1.22 to 1.99). In addition to type of anticoagulant, prior liver, gallbladder and kidney disease, cancer, anaemia, heart failure and alcoholism significantly predicted liver injury hospitalisation. A predictive model including these variables had adequate discriminative ability (C-statistic 0.67, 95{\%} CI 0.64 to 0.70). Conclusions: Among patients with non-valvular AF, DOACs were associated with lower risk of liver injury hospitalisation compared with warfarin, with dabigatran showing the lowest risk.",
author = "Alvaro Alonso and MacLehose, {Richard F.} and Chen, {Lin Y.} and Bengtson, {Lindsay G.S.} and Alanna Chamberlain and Norby, {Faye L.} and Lutsey, {Pamela L.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1136/heartjnl-2016-310586",
language = "English (US)",
volume = "103",
pages = "834--839",
journal = "Heart",
issn = "1355-6037",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation

AU - Alonso, Alvaro

AU - MacLehose, Richard F.

AU - Chen, Lin Y.

AU - Bengtson, Lindsay G.S.

AU - Chamberlain, Alanna

AU - Norby, Faye L.

AU - Lutsey, Pamela L.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Objective: To assess the risk of liver injury hospitalisation in patients with atrial fibrillation (AF) after initiation of direct oral anticoagulants (DOACs) or warfarin and to determine predictors of liver injury hospitalisation in this population. Methods: We studied 113 717 patients (mean age 70, 39% women) with AF included in the MarketScan Commercial and Medicare Supplemental databases with a first prescription for oral anticoagulation after 4 November 2011, followed through 31 December 2014. Of these, 56 879 initiated warfarin, 17 286 initiated dabigatran, 30 347 initiated rivaroxaban and 9205 initiated apixaban. Liver injury hospitalisation and comorbidities were identified from healthcare claims. Results: During a median follow-up of 12 months, 960 hospitalisations with liver injury were identified. Rates of liver injury hospitalisation ( per 1000 person-years) by oral anticoagulant were 9.0 (warfarin), 4.0 (dabigatran), 6.6 (rivaroxaban) and 5.6 (apixaban). After multivariable adjustment, liver injury hospitalisation rates were lower in initiators of DOACs compared with warfarin: HR (95% CI) of 0.57 (0.46 to 0.71), 0.88 (0.75 to 1.03) and 0.70 (0.50 to 0.97) for initiators of dabigatran, rivaroxaban, and apixaban, respectively (vs. warfarin). Compared with dabigatran initiators, rivaroxaban initiators had a 56% increased risk of liver injury hospitalisation (HR 1.56, 95% CI 1.22 to 1.99). In addition to type of anticoagulant, prior liver, gallbladder and kidney disease, cancer, anaemia, heart failure and alcoholism significantly predicted liver injury hospitalisation. A predictive model including these variables had adequate discriminative ability (C-statistic 0.67, 95% CI 0.64 to 0.70). Conclusions: Among patients with non-valvular AF, DOACs were associated with lower risk of liver injury hospitalisation compared with warfarin, with dabigatran showing the lowest risk.

AB - Objective: To assess the risk of liver injury hospitalisation in patients with atrial fibrillation (AF) after initiation of direct oral anticoagulants (DOACs) or warfarin and to determine predictors of liver injury hospitalisation in this population. Methods: We studied 113 717 patients (mean age 70, 39% women) with AF included in the MarketScan Commercial and Medicare Supplemental databases with a first prescription for oral anticoagulation after 4 November 2011, followed through 31 December 2014. Of these, 56 879 initiated warfarin, 17 286 initiated dabigatran, 30 347 initiated rivaroxaban and 9205 initiated apixaban. Liver injury hospitalisation and comorbidities were identified from healthcare claims. Results: During a median follow-up of 12 months, 960 hospitalisations with liver injury were identified. Rates of liver injury hospitalisation ( per 1000 person-years) by oral anticoagulant were 9.0 (warfarin), 4.0 (dabigatran), 6.6 (rivaroxaban) and 5.6 (apixaban). After multivariable adjustment, liver injury hospitalisation rates were lower in initiators of DOACs compared with warfarin: HR (95% CI) of 0.57 (0.46 to 0.71), 0.88 (0.75 to 1.03) and 0.70 (0.50 to 0.97) for initiators of dabigatran, rivaroxaban, and apixaban, respectively (vs. warfarin). Compared with dabigatran initiators, rivaroxaban initiators had a 56% increased risk of liver injury hospitalisation (HR 1.56, 95% CI 1.22 to 1.99). In addition to type of anticoagulant, prior liver, gallbladder and kidney disease, cancer, anaemia, heart failure and alcoholism significantly predicted liver injury hospitalisation. A predictive model including these variables had adequate discriminative ability (C-statistic 0.67, 95% CI 0.64 to 0.70). Conclusions: Among patients with non-valvular AF, DOACs were associated with lower risk of liver injury hospitalisation compared with warfarin, with dabigatran showing the lowest risk.

UR - http://www.scopus.com/inward/record.url?scp=85009454901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009454901&partnerID=8YFLogxK

U2 - 10.1136/heartjnl-2016-310586

DO - 10.1136/heartjnl-2016-310586

M3 - Article

C2 - 28057799

AN - SCOPUS:85009454901

VL - 103

SP - 834

EP - 839

JO - Heart

JF - Heart

SN - 1355-6037

IS - 11

ER -